Revance Therapeutics Inc (RVNC) Releases Earnings Results, Misses Expectations By $-0.02 EPS

Revance Therapeutics Inc (RVNC) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.88 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.86. The company posted revenue of $.80 million in the period, compared to analysts expectations of $.06 million.

Many Wall Street Analysts have commented on Revance Therapeutics Inc. Revance Therapeutics Inc was Downgraded by Brean Capital to ” Hold” on Jun 14, 2016. Shares were Reiterated by Piper Jaffray on Jun 14, 2016 to “Overweight” and Lowered the Price Target to $ 35 from a previous price target of $54 .Shares were Reiterated by SunTrust on Jun 14, 2016 to “Buy” and Lowered the Price Target to $ 22 from a previous price target of $46 .

Revance Therapeutics Inc closed down -0.43 points or -3.25% at $12.82 with 2,33,086 shares getting traded on Tusday. Post opening the session at $13.19, the shares hit an intraday low of $12.77 and an intraday high of $13.44 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jun 15, 2016, Curtis Ruegg (EVP, Technical Operations) sold 1,000 shares at $18.25 per share price. According to the SEC, on Nov 18, 2015, Arthur Peter Bertolino (EVP and Chief Medical Officer) sold 7,753 shares at $39.33 per share price.

Revance Therapeutics Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on the development manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through two dose formulations topical product candidate RT001 and injectable product candidate RT002. RT001 is a non-injectable dose form. RT001 is being studied for aesthetic indications such as crow’s feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). It is in a Phase III development program of RT001 in North America for the treatment of crow’s feet lines. RT002 is an injectable formulation of botulinum toxin designed to be targeted and longer lasting. RT002 is being studied for aesthetic indications such as glabellar (frown) lines and therapeutic uses such as muscle movement disorders.

Revance Therapeutics Inc

Leave a Reply

Revance Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Revance Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.